Metagenomics in Healthcare Market Report 2026

The metagenomics in healthcare market size has grown rapidly in recent years. It will grow from $2.44 billion in 2025 to $2.87 billion in 2026 at a compound annual growth rate (CAGR) of 17.8%. The growth in the historic period can be attributed to advancements in sequencing technologies, increased incidence of infectious diseases, expansion of microbiome research programs, rising demand for culture-independent diagnostics, availability of clinical-grade sequencing workflows.

The metagenomics in healthcare market size is expected to see rapid growth in the next few years. It will grow to $5.46 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing adoption of precision infectious disease diagnostics, rising investments in microbiome therapeutics, expansion of genomic epidemiology initiatives, growing integration of ai in microbial analysis, increasing focus on personalized treatment strategies. Major trends in the forecast period include increasing adoption of metagenomic diagnostics in clinical settings, growing use of microbiome-based disease profiling, rising integration of ngs in infection management, expansion of personalized microbial therapeutics research, enhanced focus on rapid pathogen identification.

The increasing prevalence of infectious diseases is expected to drive the growth of the metagenomics in healthcare market going forward. Infectious diseases are caused by pathogens that spread across populations. Their rising prevalence is linked to increased travel. Metagenomics enables rapid pathogen identification and outbreak control by analyzing complex microbial communities. For instance, in February 2024, tuberculosis cases in England increased by 10.7%. Therefore, the growing prevalence of infectious diseases is supporting the growth of the metagenomics in healthcare market.

Leading companies operating in the metagenomics in healthcare market are focusing on developing innovative solutions, such as microbial community profiling, to enhance disease diagnostics, enable personalized therapies, and advance precision medicine. Microbial community profiling refers to the comprehensive analysis and characterization of diverse microbial populations within a specific environment or sample using sequencing and bioinformatics tools to identify their composition, diversity, and functional roles. For instance, in August 2024, MGI Tech Co. Ltd., a China-based biotechnology company, launched a Human Microbiome Metagenomics Sequencing Package to support microbial research and healthcare applications. It delivers an automated, end-to-end microbial community profiling workflow for efficient analysis of human microbiome diversity, function, and disease associations using validated high-throughput platforms. The solution reduces manual effort, improves reproducibility, and lowers costs, making large-scale and clinical microbiome research more accessible. Researchers benefit from rapid and accurate microbial identification along with adaptable throughput, supporting biomarker discovery and advancing translational health research.

In May 2025, Mapmygenome India Limited, an India-based genomics and diagnostics company, acquired Microbiome Insights Inc. for an undisclosed amount. Through this acquisition, Mapmygenome seeks to expand its microbiome sequencing and analysis capabilities, strengthen its North American presence, and enhance its personalized health and genomics service offerings. Microbiome Insights Inc. is a Canada-based biotechnology company that provides metagenomics solutions for healthcare.

Major companies operating in the metagenomics in healthcare market are F. Hoffmann-La Roche AG, Eurofins Scientific, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., BGI Genomics Co. Ltd., Novogene Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., MedGenome Labs Limited, Zymo Research Corporation, BaseClear B.V., Psomagen Inc., Karius Inc., Microsynth AG, Macrogen Inc., Norgen Biotek Corp., Tiny Health Inc., CosmosID Inc., Kanvas Biosciences Inc., Phase Genomics Inc., Wobble Genomics Inc.

North America was the largest region in the metagenomics in healthcare market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metagenomics in healthcare market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metagenomics in healthcare market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the metagenomics in healthcare market by increasing costs of imported sequencing instruments, extraction kits, reagents, and bioinformatics infrastructure. Hospitals, diagnostic laboratories, and research institutes in North America and Europe are most affected due to dependence on imported genomic technologies, while Asia-Pacific faces higher consumable costs. These tariffs are raising diagnostic service prices and slowing adoption in cost-sensitive settings. However, they are also encouraging domestic kit manufacturing, regional sequencing capacity expansion, and localized bioinformatics development to strengthen long-term market resilience.

The metagenomics in healthcare market research report is one of a series of new reports that provides metagenomics in healthcare market statistics, including metagenomics in healthcare industry global market size, regional shares, competitors with a metagenomics in healthcare market share, detailed metagenomics in healthcare market segments, market trends and opportunities, and any further data you may need to thrive in the metagenomics in healthcare industry. This metagenomics in healthcare market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metagenomics in healthcare refers to the analysis of genetic material obtained directly from clinical or environmental samples to study complete microbial communities without culturing. It helps identify pathogens, evaluate microbiome composition, and detect microbial changes associated with disease, enabling accurate diagnosis, personalized treatment, and improved infection control.

The primary types of metagenomics in healthcare are sample extraction kits and metagenomics kits. Sample extraction kits are commercially available products designed to efficiently isolate deoxyribonucleic acid or ribonucleic acid from biological samples. These utilize technologies such as next-generation sequencing, polymerase chain reaction, and microarray and follow workflows including sample collection, DNA extraction, library preparation, and sequencing. Applications include infectious disease diagnosis, genomic epidemiology, personalized medicine, microbiome analysis, and drug discovery, serving end-users such as hospitals, diagnostic laboratories, research institutes, pharmaceutical companies, and biotechnology companies.

The metagenomics in healthcare market consists of revenues earned by entities by providing services such as bioinformatics analysis, microbial diagnostics, and drug discovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The metagenomics in the healthcare market also includes sales of sequencing platforms, reagents, consumables, and bioinformatics tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.